Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
AI risk raises the bar for outsourced pharma marketing deals
Axios Pro Exclusive Content 51 mins ago…
Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Buy at Wall Street Zen
Royalty Pharma (NASDAQ:RPRX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a 'strong-buy' rating to a 'buy' rating in a report issued on Saturday, Wall Street Zen reports. How Royalty Pharma Prints Cash…
Ascendis Pharma A/S (NASDAQ:ASND) Cut to Hold at Wall Street Zen
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a 'buy' rating to a 'hold' rating in a report issued on Saturday, Wall Street Zen reports. Get Ascendis Pharma A/S alerts: Can…
Ascendis Pharma A/S (NASDAQ:ASND) Stock Rated 'Buy' by Wall Street Brokerages
Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have received a consensus recommendation of 'Buy' from the twenty-one research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a…
Spyglass Pharma, Inc. (NASDAQ:SGP) Stock Has Average Target Price of $44.00
Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has received a consensus recommendation of 'Moderate Buy' from the eight ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a…
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions BridgeBio Pharma NASDAQ: BBIO expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO…
State Street Corp Makes New $10.50 Million Investment in Avalyn Pharma Inc. $AVLN
State Street Corp acquired a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 318,995 shares of the company's stock, valued at…
How Chinese biotech is graduating from licensing deals to broader partnerships
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based…
Pfizer: Buy Before The Street Catches Up To Its Own Numbers (NYSE:PFE)
Pfizer is rated buy, not for deep value, but due to a disconnect between management's bullish long-term growth guidance and a flat consensus earnings curve. Consensus models a permanent post-2026 revenue/EPS decline, but PFE's $13B product base is…
Caesars Taken Private By Fertitta Reaches Key Milestone, But Caution Is A Virtue (CZR)
Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…
The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady (NASDAQ:CBIO)
Crescent Biopharma remains a Buy, balancing early clinical progress with robust liquidity and sector opportunity. CBIO's lead asset, CR-001, is in phase 1/2 trials with proof-of-concept data expected in Q1 2027; additional pipeline assets advance…
Akamai: Deal With Anthropic Boosts Existing AI-Driven Tailwind; Risks Cloud Horizon (AKAM)
Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…
Nuclidium CEO: 'Our challenge remains the demonstration of clinical efficacy and utility'
Series CEO spotlight, Episode 19: Could Nuclidium become the Novartis of tomorrow? That is certainly the hope of the investors who have just injected more than CHF100 million into this promising Basel-based biotech start-up. Founded in 2021…
'I'm not JD Vance': the Appalachia memoir author running for Congress
Virginia's sixth congressional district has been in Republican hands for over 33 years, but Beth Macy, a longtime reporter with the Roanoke Times and author of Dopesick, a powerful account of the opioid crisis that swept through Appalachia two…
Existing drug helps bladder cells destroy hidden urinary tract infections
Urinary tract infections, or UTIs, are among the most common bacterial infections, caused mostly by the uropathogenic bacterium Escherichia coli. But even after antibiotic treatment, a large number of patients experience another UTI. One reason is…
Receive a Daily briefing on Pharma Industry News
Get Started